{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:46:46Z","timestamp":1791380806872,"version":"4.3.3"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Current medical therapies in idiopathic subglottic stenosis (iSGS) are insufficient in preventing the development and progression of scar tissue. An inhibitor of mammalian target of rapamycin, everolimus is an immunosuppressive medication shown to be effective in reducing fibrosis across a variety of fibroproliferative disorders, including preclinical models of iSGS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effect of oral everolimus on postoperative recurrence of stenosis in iSGS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This open-label, single-arm, phase 1, nonrandomized clinical trial analyzed 7 perimenopausal participants diagnosed with iSGS and followed-up at a tertiary care academic center for 6 months after dilation surgery. The trial was conducted from November 1, 2022, through May 15, 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Participants took a 1.5-mg daily oral dose of everolimus for 42 days after surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcomes and measures<\/jats:title><jats:p>The primary outcome measure was safety as determined by adverse events. Secondary outcome measures included change in peak expiratory flow from baseline through 180 days after surgery; change in the luminal area, measured by computed tomographic (CT) scan, from the 14th and the 180th day; and changes in quality-of-life scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 8 perimenopausal participants, 7 (median age, 50 years [IQR, 45.0-52.5 years]) completed the study. Compared with baseline at all time points, there was an increase in peak expiratory flow. The median difference in liters per minute was 125 (95% CI, 90-270) on day 7 after surgery; 150 (95% CI, 110-290) on day 14; 138 (95% CI, 116-280) on day 28; 160 (95% CI, 100-270) on day 42; 155 (95% CI, 110-270) on day 60; 140 (95% CI, 100-270) on day 90; and 100 (95% CI, 20-240) on day 180. A decrease in the CT luminal area was observed from the day-14 measure to the day-180 measure (median stenosis, 7.2%; IQR, 1.9%-15.4%). During the trial, 1 participant (14.3%) each developed oral ulcers, a urinary tract infection, and a skin infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this interventional nonrandomized clinical trial of iSGS, adjuvant everolimus was well-tolerated with minor adverse events. Participants sustained postdilation peak expiratory flow for 13 weeks. These results support proceeding to a phase 2 trial to study drug efficacy and a more detailed investigation of adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05153668?id=NCT05153668&amp;amp;amp;rank=1\">NCT05153668<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2024.2886","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T15:58:35Z","timestamp":1727366315000},"page":"1029","source":"Crossref","is-referenced-by-count":8,"title":["Oral Everolimus Following Dilation in Idiopathic Subglottic Stenosis"],"prefix":"10.1001","volume":"150","author":[{"given":"Raymond J.","family":"So","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mafla","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee","family":"Chan-Li","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan","family":"Lina","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gelbard","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Motz","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Hillel","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"obr240003r1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jamaoto.2019.3022","article-title":"Comparative treatment outcomes for patients with idiopathic subglottic stenosis.","volume":"146","author":"Gelbard","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"obr240003r2","doi-asserted-by":"publisher","first-page":"E1062","DOI":"10.1002\/lary.29013","article-title":"Endoscopic wedge excisions with Co2 laser for subglottic stenosis.","volume":"131","author":"Ekbom","year":"2021","journal-title":"Laryngoscope"},{"issue":"5","key":"obr240003r3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1177\/01945998211028163","article-title":"Endoscopic resection and mucosal reconstitution with epidermal grafting: a pilot study in idiopathic subglottic stenosis.","volume":"166","author":"Davis","year":"2022","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"obr240003r4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.otot.2023.05.009","article-title":"Office based steroid injections for subglottic stenosis.","volume":"34","author":"Franco","year":"2023","journal-title":"Oper Tech Otolaryngol\u2014Head Neck Surg"},{"issue":"9","key":"obr240003r5","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1002\/lary.30449","article-title":"Impact of serial intralesional steroid injections on idiopathic subglottic stenosis.","volume":"133","author":"Hoffman","year":"2023","journal-title":"Laryngoscope"},{"issue":"12","key":"obr240003r6","doi-asserted-by":"publisher","first-page":"E2880","DOI":"10.1002\/lary.29675","article-title":"Impact of adjuvant medical therapies on surgical outcomes in idiopathic subglottic stenosis.","volume":"131","author":"Hoffman","year":"2021","journal-title":"Laryngoscope"},{"issue":"1","key":"obr240003r7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/ijo.2021.5234","article-title":"Everolimus therapy and side-effects: a systematic review and meta-analysis.","volume":"59","author":"Arena","year":"2021","journal-title":"Int J Oncol"},{"issue":"2","key":"obr240003r8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5500\/wjt.v4.i2.133","article-title":"Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.","volume":"4","author":"Fern\u00e1ndez-Yunquera","year":"2014","journal-title":"World J Transplant"},{"issue":"18","key":"obr240003r9","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1111\/bph.15898","article-title":"Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.","volume":"179","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2022","journal-title":"Br J Pharmacol"},{"key":"obr240003r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120150","article-title":"The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats.","volume":"288","author":"Shigematsu","year":"2022","journal-title":"Life Sci"},{"issue":"23","key":"obr240003r11","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1056\/NEJMoa1610227","article-title":"Everolimus-eluting stents or bypass surgery for left main coronary artery disease.","volume":"375","author":"Stone","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"obr240003r12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1039\/C8BM01623B","article-title":"Engineering an immunomodulatory drug-eluting stent to treat laryngotracheal stenosis.","volume":"7","author":"Duvvuri","year":"2019","journal-title":"Biomater Sci"},{"issue":"11","key":"obr240003r13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1172\/jci.insight.158456","article-title":"Sirolimus-eluting airway stent reduces profibrotic Th17 cells and inhibits laryngotracheal stenosis.","volume":"8","author":"Motz","year":"2023","journal-title":"JCI Insight"},{"issue":"10","key":"obr240003r14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14737175.2019.1635457","article-title":"Everolimus as adjunctive therapy for tuberous sclerosis complex\u2013associated partial-onset seizures.","volume":"19","author":"Lechuga","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"obr240003r15","doi-asserted-by":"publisher","first-page":"E2841","DOI":"10.1002\/lary.29760","article-title":"Modeling recurrence in idiopathic subglottic stenosis with mobile peak expiratory flow.","volume":"131","author":"Kimura","year":"2021","journal-title":"Laryngoscope"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2823997\/jamaotolaryngology_so_2024_br_240003_1731519067.54908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T16:01:15Z","timestamp":1731600075000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2823997"}},"subtitle":["A Phase 1 Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2024.2886","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}